Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1062a in Advanced/Unresectable NSCLC
NCT04940325Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2021
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Primary endpoint: Objective Response Rate at 4 months. Started May 2021; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04940325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940325.